Patient Advocate's Notes From 8th International Kidney Cancer Symposium
  Eighth International Kidney Cancer Symposium September 2009     Management of Small Renal Masses and Localized Renal Carcinoma Case Presentation and Background Robert G. Uzzo, M.D., FACS There are a lot of options available to manage small (
Source: Kidney Cancer Association - January 4, 2010 Category: Urology & Nephrology Source Type: news

Notes from the 8th International Symposium
Patient advocates generously volunteered their time to take notes at the recent 8th International Kidney Cancer Symposium, in Chicago.  These notes are intended to capture the essence of this important medical meeting and convey it in a way that is useful to patients, survivors, and their families.  The first installment sumarizes the Saturday morning session. Integration of Surgical and Systemic Therapy in Metastatic RCC  This session was opened by Dr. Bradley Leibovich who presented two cases on which the audience voted on methods to integrate surgery with systemic treatment interventions.  T...
Source: Kidney Cancer Association - November 17, 2009 Category: Urology & Nephrology Source Type: news

Notes from the 8th International Symposium
Patient advocates generously volunteered their time to take notes at the recent 8th International Kidney Cancer Symposium, in Chicago.  These notes are intended to capture the essence of this important medical meeting and convey it in a way that is useful to patients, survivors, and their families.  The first installment sumarizes the Saturday morning session.Integration of Surgical and Systemic Therapy in Metastatic RCC This session was opened by Dr. Bradley Leibovich who presented two cases on which the audience voted on methods to integrate surgery with systemic treatment interventions.  The diversit...
Source: Kidney Cancer Association - November 17, 2009 Category: Urology & Nephrology Source Type: news

FDA Approves Avastin for the Most Common Type of Kidney Cancer
Click here for the full press release.08/03/2009 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 3, 2009 Category: Urology & Nephrology Source Type: news

NCCN Updates Guidelines for Central Nervous System (CNS) Cancers
NCCN recently updated the NCCN Guidelines for Central Nervous System (CNS) Cancers. Important new updates include the recommendation to use bevacizumab as a single agent for recurrent glioblastoma multiforme in CNS cancers, the integration of a patient's Karnofsky Performance Status (KPS) score into treatment decisions, and an adjusted age range for adjuvant therapy options in patients with low grade gliomas. May 18, 2009 FORT WASHINGTON, PA - The National Comprehensive Cancer Network (NCC... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - May 18, 2009 Category: Cancer & Oncology Source Type: news

Kidney Cancer Association Applauds UK Drug Approval
      Change of Tack Shows Policy Shift and Saves Lives Evanston, IL, February 5, 2009 – The National Institute of Health and Clinical Excellence (NICE), the review body for the UK’s National Health Service, yesterday reversed an earlier decision and approved a drug for metastatic renal cell carcinoma. The decision marks an enormous victory for advanced-stage kidney cancer patients as well as the advocates who applied pressure on NICE to change their policy regarding lifesaving drugs for terminal patients.   “This decision demonstrates the power of a unified voice,” said W...
Source: Kidney Cancer Association - February 5, 2009 Category: Urology & Nephrology Source Type: news

Kidney Cancer Association Applauds UK Drug Approval
   Change of Tack Shows Policy Shift and Saves LivesEvanston, IL, February 5, 2009– The National Institute of Health and Clinical Excellence (NICE), the review body for the UK’s National Health Service, yesterday reversed an earlier decision and approved a drug for metastatic renal cell carcinoma. The decision marks an enormous victory for advanced-stage kidney cancer patients as well as the advocates who applied pressure on NICE to change their policy regarding lifesaving drugs for terminal patients. “This decision demonstrates the power of a unified voice,” said William Br...
Source: Kidney Cancer Association - February 5, 2009 Category: Urology & Nephrology Source Type: news

Early Data on Amgen ’s Anti-Angiogenesis Pipeline Molecules Suggest Biologic Activity Across Tumor Types
Amgen today announced results from preclinical studies suggesting a significantly greater reduction in tumor growth when AMG 386, a recombinant Fc-peptide fusion protein (peptibody) designed to bind angiopoietins 1 and 2, thereby inhibiting Tie2 dependent stimulation of endothelial cells, was combined with either of two vascular endothelial growth factor (VEGF) inhibitors -- bevacizumab or motesanib diphosphate (AMG 706) -- compared with either treatment alone (p < 0.05). 04/13/2008 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 15, 2008 Category: Urology & Nephrology Source Type: news

Novartis kidney cancer drug clears key hurdle
Everolimus (RAD001) significantly extends progression-free survival in advanced kidney cancer patients after failure of other targeted therapy  Outstanding interim results cause independent data monitoring committee to immediately share findings; patients on placebo to be offered everolimus  Everolimus (RAD001) tablet, taken once daily, demonstrated highly effective anti-tumor activity through continuous targeted inhibition of mTOR  Results of RECORD-1 trial address unmet medical need in renal cell cancer with worldwide regulatory filings planned for second half of 2008  Complete results to ...
Source: Kidney Cancer Association - February 28, 2008 Category: Urology & Nephrology Source Type: news

Novartis kidney cancer drug clears key hurdle
Everolimus (RAD001) significantly extends progression-free survival in advanced kidney cancer patients after failure of other targeted therapy Outstanding interim results cause independent data monitoring committee to immediately share findings; patients on placebo to be offered everolimus Everolimus (RAD001) tablet, taken once daily, demonstrated highly effective anti-tumor activity through continuous targeted inhibition of mTOR Results of RECORD-1 trial address unmet medical need in renal cell cancer withworldwide regulatory filings planned for second half of 2008 Complete results to be submitted as l...
Source: Kidney Cancer Association - February 28, 2008 Category: Urology & Nephrology Source Type: news

KCA-ASCO Young Investigator Award
KCA and the and the ASCO Grants Selection Committee announce the selection of the 2007 Young Investigator Award: Patricia Tang, MD, Princess Margaret Hospital Abstract With the advent of anti-angiogenic therapies (AAT) for cancer treatment, a number of adverse effects have been identified in patients; importantly these include proteinuria (due to disruption of the glomerular filtration barrier) and hypertension.    Hypertension appears to be a class effect of AAT, whereas proteinuria has been reported with bevacizumab, VEGF Trap, and AZD2171.  The physiological mechanisms underlying the hypertension ...
Source: Kidney Cancer Association - March 4, 2007 Category: Urology & Nephrology Source Type: news

KCA-ASCO Young Investigator Award
KCA and the and the ASCO Grants Selection Committee announce the selection of the 2007 Young Investigator Award:Patricia Tang, MD, Princess Margaret HospitalAbstractWith the advent of anti-angiogenic therapies (AAT) for cancer treatment, a number of adverse effects have been identified in patients; importantly these include proteinuria (due to disruption of the glomerular filtration barrier) and hypertension.    Hypertension appears to be a class effect of AAT, whereas proteinuria has been reported with bevacizumab, VEGF Trap, and AZD2171.  The physiological mechanisms underlying the hypertension and pr...
Source: Kidney Cancer Association - March 4, 2007 Category: Urology & Nephrology Source Type: news

NCCN Releases Updated Treatment Guidelines for Non-Small Cell Lung Cancer
Recent updates for leukemia and bone cancer also posted on www.nccn.org JENKINTOWN, Pa., October 27, 2005 — The National Comprehensive Cancer Network (NCCN) announces the release of newly updated NCCN Clinical Practice Guidelines in Oncology for non-small cell lung cancer (NSCLC). Notable changes in NCCN’s updated NSCLC guidelines are the inclusion of bevacizumab (Genentech’s Avastin) plus chemotherapy as first-line treatment for advanced NSCLC, as well as newly defined principles of patholo... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - October 27, 2005 Category: Cancer & Oncology Source Type: news